Reduced Chance of Hearing Loss Associated With Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis

Antimicrobial Agents and Chemotherapy - United States
doi 10.1128/aac.01400-16
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society for Microbiology

Related search

Therapeutic Drug Management: Is It the Future of Multidrug-Resistant Tuberculosis Treatment?

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2013English

P56 Treatment of Multidrug Resistant Tuberculosis: Where Are the Guidelines for Monitoring?

Thorax
PulmonaryRespiratory Medicine
2011English

Reducing Harm in the Treatment of Multidrug-Resistant Tuberculosis

The Lancet
Medicine
2018English

Multidrug and Extensively Drug-Resistant Tuberculosis

Infectious Disease Clinics of North America
Infectious DiseasesMicrobiology
2019English

Clofazimine for the Treatment of Multidrug-Resistant Tuberculosis

Clinical Microbiology and Infection
MedicineInfectious DiseasesMicrobiology
2019English

The Validation of Cycloserine Efficacy in Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Beijing, China

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2018English

Transmission of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in a Metropolitan City

European Respiratory Journal
MedicinePulmonaryRespiratory Medicine
2012English

Pharmacokinetics of Levofloxacin in Multidrug- And Extensively Drug-Resistant Tuberculosis Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2017English

Rifabutin: Is It Useful in the Treatment of Multidrug-Resistant Tuberculosis?

International Journal of Infectious Diseases
MedicineInfectious DiseasesMicrobiology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy